STOCK TITAN

Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. Announce Exit from Pharmaceutics International, Inc.

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Pharmaceutics International, Inc. (Pii) has been acquired by Jabil Inc. (NYSE: JBL) in an all-cash transaction for an undisclosed amount. The sale marks the exit of a consortium of investors including Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Inc.

Pii, based in Hunt Valley, Maryland, is a contract development and manufacturing organization specializing in aseptic and sterile injectable pharmaceutical products. The company has provided development and manufacturing services for both NDA and aNDA products for nearly three decades, offering formulation capabilities across virtually all dosage forms and specializing in complex formulations.

The company operates on both a fee-for-service basis for pharmaceutical clients and a profit-share or royalty basis for marketing partners.

Pharmaceutics International, Inc. (Pii) è stata acquisita da Jabil Inc. (NYSE: JBL) in una transazione interamente in contante per un importo non divulgato. La vendita segna l’uscita di un consorzio di investitori tra cui Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital e Pharmascience Inc.

Pii, con sede a Hunt Valley, Maryland, è un'organizzazione di sviluppo e produzione a contratto specializzata in prodotti farmaceutici iniettabili asettici e sterili. L'azienda ha fornito servizi di sviluppo e produzione per prodotti sia NDA che aNDA per quasi tre decenni, offrendo capacità di formulazione in praticamente tutte le forme di dosaggio e specializzandosi in formulazioni complesse.

L'azienda opera sia su base di pagamento per servizio per i clienti farmaceutici che su base di condivisione degli utili o royalty per i partner di marketing.

Pharmaceutics International, Inc. (Pii) ha sido adquirida por Jabil Inc. (NYSE: JBL) en una transacción completamente en efectivo por un monto no divulgado. La venta marca la salida de un consorcio de inversores que incluye a Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital y Pharmascience Inc.

Pii, con sede en Hunt Valley, Maryland, es una organización de desarrollo y fabricación por contrato especializada en productos farmacéuticos inyectables asépticos y estériles. La empresa ha proporcionado servicios de desarrollo y fabricación tanto para productos NDA como aNDA durante casi tres décadas, ofreciendo capacidades de formulación en prácticamente todas las formas de dosificación y especializándose en formulaciones complejas.

La empresa opera tanto en base a tarifas por servicio para clientes farmacéuticos como en base a participación en beneficios o regalías para socios de comercialización.

Pharmaceutics International, Inc. (Pii)Jabil Inc. (NYSE: JBL)에 의해 비공식적인 금액으로 현금 거래로 인수되었습니다. 이 판매는 Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital 및 Pharmascience Inc.를 포함한 투자자 컨소시엄의 퇴장을 의미합니다.

메릴랜드주 헌트밸리에 본사를 두고 있는 Pii는 무균 및 멸균 주사 제형의 제약 제품을 전문으로 하는 계약 개발 및 제조 조직입니다. 이 회사는 거의 30년 동안 NDA 및 aNDA 제품에 대한 개발 및 제조 서비스를 제공했으며, 실제로 모든 제형 형태에 대한 제형 기능을 제공하고 복잡한 제형에 전문화되어 있습니다.

회사는 제약 고객을 위한 서비스 요금제와 마케팅 파트너를 위한 이익 분배 또는 로열티 기반으로 운영됩니다.

Pharmaceutics International, Inc. (Pii) a été acquis par Jabil Inc. (NYSE: JBL) dans une transaction entièrement en espèces pour un montant non divulgué. La vente marque le départ d'un consortium d'investisseurs, y compris Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital et Pharmascience Inc.

Pii, basé à Hunt Valley, Maryland, est une organisation de développement et de fabrication sous contrat spécialisée dans les produits pharmaceutiques injectables aseptiques et stériles. L'entreprise a fourni des services de développement et de fabrication pour des produits à la fois NDA et aNDA pendant près de trois décennies, offrant des capacités de formulation dans pratiquement toutes les formes posologiques et se spécialisant dans des formulations complexes.

L'entreprise opère à la fois sur une base de frais de service pour ses clients pharmaceutiques et sur une base de partage des bénéfices ou de redevances pour ses partenaires de marketing.

Pharmaceutics International, Inc. (Pii) wurde von Jabil Inc. (NYSE: JBL) in einer Bartransaktion zu einem nicht bekannt gegebenen Betrag erworben. Der Verkauf markiert den Ausstieg eines Konsortiums von Investoren, zu denen Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital und Pharmascience Inc. gehören.

Pii, mit Sitz in Hunt Valley, Maryland, ist eine Vertragsentwicklungs- und -produktionsorganisation, die sich auf aseptische und sterile injizierbare Arzneimittelprodukte spezialisiert hat. Das Unternehmen bietet seit fast drei Jahrzehnten Entwicklungs- und Produktionsdienste für NDA- und aNDA-Produkte an und bietet Formulierungsfähigkeiten in nahezu allen Darreichungsformen an und hat sich auf komplexe Formulierungen spezialisiert.

Das Unternehmen arbeitet sowohl auf einer Gebührenbasis für pharmazeutische Kunden als auch auf einer Gewinnbeteiligungs- oder Lizenzbasis für Marketingpartner.

Positive
  • Acquisition by larger, NYSE-listed company Jabil Inc. (JBL)
  • All-cash transaction structure indicates strong liquidity
  • Strategic expansion into pharmaceutical manufacturing for Jabil
Negative
  • Undisclosed transaction value creates uncertainty about deal terms

Insights

The acquisition of Pharmaceutics International (Pii) marks a significant strategic expansion for Jabil in the high-growth Contract Development and Manufacturing Organization (CDMO) sector. This deal is particularly noteworthy as it provides Jabil immediate access to specialized capabilities in aseptic and sterile injectable pharmaceutical manufacturing, a high-margin segment of the CDMO market.

The strategic value of this acquisition lies in three key areas: First, it diversifies Jabil's healthcare portfolio beyond medical devices into pharmaceutical manufacturing, positioning the company to capture a larger share of the expanding CDMO market, which is projected to grow at a CAGR of 7.5% through 2028. Second, Pii's three-decade expertise in complex formulations and regulatory compliance provides Jabil with valuable intellectual property and established relationships with pharmaceutical clients. Third, the deal presents significant cross-selling opportunities, allowing Jabil to offer end-to-end solutions to its existing healthcare customers.

From an operational perspective, the all-cash transaction structure suggests Jabil's strong financial position and confidence in immediate value creation. The integration of Pii's Hunt Valley facility adds a strategic East Coast presence to Jabil's manufacturing network, potentially improving operational efficiency and customer service capabilities. The acquisition is expected to be accretive to Jabil's healthcare segment margins, given Pii's focus on high-value, complex formulations and its mix of fee-for-service and profit-sharing revenue models.

NEW YORK--(BUSINESS WIRE)-- A consortium of investors led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. today announced they have exited their equity stake in Pharmaceutics International, Inc. (“Pii”), a contract development and manufacturing organization, and have closed on an undisclosed all-cash transaction to sell the company to Jabil Inc. (NYSE: JBL), a global leader in engineering, manufacturing, and supply chain solutions.

Pii is a contract development and manufacturing business, based in Hunt Valley, Maryland, that specializes in the production of aseptic and sterile injectable pharmaceutical products. The company has been offering development and manufacturing services to pharmaceutical clients, for both NDA and aNDA products, for nearly three decades. Pii has formulation capabilities across virtually all dosage forms and is a sought-after partner for the most complex formulations. The company develops and manufactures drug products for its clients on a fee-for-service basis, and for its marketing partners on a profit-share or royalty basis.

“We have greatly valued our partnership with Signet, Athyrium, Hildred and Pharmascience over the past decade,” said John Fowler, President and CEO of Pii. “Their collective operating expertise and breadth of experience across the healthcare ecosystem were invaluable in helping Pii strategically scale and enhance and expand our suite of capabilities. The firms’ Operating Partners played a critical role, working closely with management over an extended period of time to drive value at the company. All of us at Pii appreciate their long-standing commitment and support over the years. We are excited about our future and looking forward to building on our momentum and success with our new partners at Jabil.”

Sidley Austin LLP acted as legal counsel for Pii.

About Pharmaceutics International, Inc.

Pii is a privately held contract development and manufacturing organization providing dosage form development and manufacturing services to the global pharmaceutical industry. Headquartered in Hunt Valley, Maryland with European facilities in the UK, services include preformulation testing, formulation development, clinical and commercial CGMP manufacturing of solid, parenteral, inhalation, semi-solid and liquid dosage forms, clinical packaging and labeling, and analytical services. Pii's facilities include manufacturing and containment suites, automated packaging lines and a wide selection of equipment. For more information, please visit www.pharm-int.com.

About Signet Healthcare Partners

Signet Healthcare Partners is a leading provider of growth capital to innovative healthcare companies, with a focus on the pharmaceutical and medical device sectors. With over 25 years of experience, Signet has raised cumulative capital commitments exceeding $600 million and invested in over 60 companies. The firm works closely with its portfolio companies to drive value and accelerate growth. For more information, visit www.signethealthcarepartners.com.

About Athyrium Capital Management

Athyrium is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium advises funds with over $4.6 billion in committed capital. The Athyrium team has substantial investment experience across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals including biopharma, medical devices and products, healthcare focused services, and healthcare information technology. For more information, please visit www.athyrium.com.

About Hildred Capital

Hildred Capital is a healthcare-focused private equity firm that specializes in operationally intensive, control-oriented investments in lower middle-market companies. Hildred partners with innovative and growth-oriented management teams to build high quality businesses. The Hildred team possesses extensive experience across the healthcare industry, and seeks to leverage its unique blend of strategic, financial, commercial and operational acumen to drive strategic growth and create value for its portfolio companies and investment partners. Hildred currently has more than $2.65 billion in assets under management. For more information, please visit www.hildred.com and follow the firm on LinkedIn.

About Pharmascience Inc.

Founded in 1983, Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 47th among Canada's top 100 R&D investors with $56 million invested annually, Pharmascience Inc. is the 10th largest pharmaceutical company in Canada. Pharmascience Inc. is a leading manufacturer and marketer of prescription, generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products.

Media:

Mike Geller

Prosek

mgeller@prosek.com

Source: Hildred Capital

FAQ

What is the acquisition price for Jabil's purchase of Pharmaceutics International?

The transaction value was not disclosed in the announcement, though it was specified as an all-cash deal.

What type of manufacturing capabilities does Pii bring to Jabil (JBL)?

Pii brings capabilities in aseptic and sterile injectable pharmaceutical products manufacturing, along with formulation expertise across virtually all dosage forms.

How will the Pii acquisition affect Jabil's (JBL) pharmaceutical manufacturing presence?

The acquisition expands Jabil's presence in pharmaceutical manufacturing, specifically adding capabilities in aseptic and sterile injectable products, and complex formulations.

What is Pii's business model that Jabil (JBL) is acquiring?

Pii operates on two business models: a fee-for-service basis for pharmaceutical clients and a profit-share or royalty basis for marketing partners.

Jabil Inc.

NYSE:JBL

JBL Rankings

JBL Latest News

JBL Stock Data

18.19B
107.43M
1.94%
96.2%
2.45%
Electronic Components
Printed Circuit Boards
Link
United States
ST PETERSBURG